Black Diamond Therapeutics, Inc. (BDTX) saw heightened options market activity, particularly with the September 18, 2026 $0.5 Call option, which exhibited significant implied volatility, indicating traders anticipate substantial price movement. This volatility may suggest an upcoming event that could lead to either a rally or a sell-off.
As of now, Black Diamond Therapeutics holds a Zacks Rank #3 (Hold) in the Medical – Biomedical and Genetics sector, ranking in the bottom 41% of its industry. The Zacks Consensus Estimate has shifted from an expected gain of 8 cents per share to a projected loss of 18 cents per share over the past 60 days, reflecting analysts’ concerns about the company’s financial outlook.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
